Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) | MicrobiomeTrials
Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
CompletedPHASE2INTERVENTIONAL
Trial Details
Start: 2021-12-09Est. Completion: 2024-02-05
Enrollment target: 13 participants
Locations
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Other microbiome trials you might be interested in